LONDON, March 19 /PRNewswire/ -- New clinical data from a study of 570 men published in the peer-reviewed Journal of Urology(1) support the use of PROGENSA PCA3 as a tool for diagnosing prostate cancer. The study confirms that PROGENSA PCA3, the world’s first gene-based urine test to help detect prostate cancer, can provide clinicians with valuable information that helps guide diagnosis.
